Literature DB >> 22252512

Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.

Matthew G Cottingham1, Fionnadh Carroll, Susan J Morris, Alison V Turner, Aisling M Vaughan, Melissa C Kapulu, Stefano Colloca, Loredana Siani, Sarah C Gilbert, Adrian V S Hill.   

Abstract

First-generation, E1/E3-deleted adenoviral vectors with diverse transgenes are produced routinely in laboratories worldwide for development of novel prophylactics and therapies for a variety of applications, including candidate vaccines against important infectious diseases, such as HIV/AIDS, tuberculosis, and malaria. Here, we show, for two different transgenes (both encoding malarial antigens) inserted at the E1 locus, that rare viruses containing a transgene-inactivating mutation exhibit a selective growth advantage during propagation in E1-complementing HEK293 cells, such that they rapidly become the major or sole species in the viral population. For one of these transgenes, we demonstrate that viral yield and cytopathic effect are enhanced by repression of transgene expression in the producer cell line, using the tetracycline repressor system. In addition to these transgene-inactivating mutations, one of which occurred during propagation of the pre-viral genomic clone in bacteria, and the other after viral reconstitution in HEK293 cells, we describe two other types of mutation, a small deletion and a gross rearranging duplication, in one of the transgenes studied. These were of uncertain origin, and the effects on transgene expression and viral growth were not fully characterized. We demonstrate that, together with minor protocol modifications, repression of transgene expression in HEK293 cells during viral propagation enables production of a genetically stable chimpanzee adenovirus vector expressing a malarial antigen which had previously been impossible to derive. These results have important implications for basic and pre-clinical studies using adenoviral vectors and for derivation of adenoviral vector products destined for large-scale amplification during biomanufacture.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22252512      PMCID: PMC4981243          DOI: 10.1002/bit.24342

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  30 in total

Review 1.  Pfs230: from malaria transmission-blocking vaccine candidate toward function.

Authors:  Kim C Williamson
Journal:  Parasite Immunol       Date:  2003-07       Impact factor: 2.280

2.  High throughput creation of recombinant adenovirus vectors by direct cloning, green-white selection and I-Sce I-mediated rescue of circular adenovirus plasmids in 293 cells.

Authors:  G Gao; X Zhou; M R Alvira; P Tran; J Marsh; K Lynd; W Xiao; J M Wilson
Journal:  Gene Ther       Date:  2003-10       Impact factor: 5.250

3.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

Review 4.  Use of adenovirus in vaccines for HIV.

Authors:  Steven Patterson; Timos Papagatsias; Adel Benlahrech
Journal:  Handb Exp Pharmacol       Date:  2009

5.  Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria.

Authors:  E G Rodrigues; F Zavala; D Eichinger; J M Wilson; M Tsuji
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

Review 6.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

7.  Human adenovirus type 5 recombinants expressing simian immunodeficiency virus macaque strain gag antigens.

Authors:  C Caravokyri; C R Pringle; K N Leppard
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

Review 8.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

Review 9.  Viral vectors in malaria vaccine development.

Authors:  K J Limbach; T L Richie
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

10.  Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.

Authors:  S Sridhar; A Reyes-Sandoval; S J Draper; A C Moore; S C Gilbert; G P Gao; J M Wilson; A V S Hill
Journal:  J Virol       Date:  2008-02-06       Impact factor: 5.103

View more
  26 in total

1.  Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Authors:  Anne-Marie C Andersson; Emeline Ragonnaud; Kelly E Seaton; Sheetal Sawant; Antonella Folgori; Stefano Colloca; Celia Labranche; David C Montefiori; Georgia D Tomaras; Peter J Holst
Journal:  Vaccine       Date:  2016-09-12       Impact factor: 3.641

2.  Modified MHC Class II-Associated Invariant Chain Induces Increased Antibody Responses against Plasmodium falciparum Antigens after Adenoviral Vaccination.

Authors:  Cyrielle Fougeroux; Louise Turner; Anders Miki Bojesen; Thomas Lavstsen; Peter Johannes Holst
Journal:  J Immunol       Date:  2019-03-04       Impact factor: 5.422

3.  A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.

Authors:  Matthew D J Dicks; Alexandra J Spencer; Nick J Edwards; Göran Wadell; Kalifa Bojang; Sarah C Gilbert; Adrian V S Hill; Matthew G Cottingham
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

4.  Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Authors:  Susanne H Hodgson; Katie J Ewer; Carly M Bliss; Nick J Edwards; Thomas Rampling; Nicholas A Anagnostou; Eoghan de Barra; Tom Havelock; Georgina Bowyer; Ian D Poulton; Simone de Cassan; Rhea Longley; Joseph J Illingworth; Alexander D Douglas; Pooja B Mange; Katharine A Collins; Rachel Roberts; Stephen Gerry; Eleanor Berrie; Sarah Moyle; Stefano Colloca; Riccardo Cortese; Robert E Sinden; Sarah C Gilbert; Philip Bejon; Alison M Lawrie; Alfredo Nicosia; Saul N Faust; Adrian V S Hill
Journal:  J Infect Dis       Date:  2014-10-21       Impact factor: 5.226

5.  Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.

Authors:  Rhea J Longley; Ahmed M Salman; Matthew G Cottingham; Katie Ewer; Chris J Janse; Shahid M Khan; Alexandra J Spencer; Adrian V S Hill
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

Review 6.  Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".

Authors:  Katie J Ewer; Kailan Sierra-Davidson; Ahmed M Salman; Joseph J Illingworth; Simon J Draper; Sumi Biswas; Adrian V S Hill
Journal:  Vaccine       Date:  2015-10-21       Impact factor: 3.641

7.  4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaques.

Authors:  Alexandra J Spencer; Julie Furze; Jared D Honeycutt; Alice Calvert; Saroj Saurya; Stefano Colloca; David H Wyllie; Sarah C Gilbert; Migena Bregu; Matthew G Cottingham; Adrian V S Hill
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

8.  Development of an in vitro assay and demonstration of Plasmodium berghei liver-stage inhibition by TRAP-specific CD8+ T cells.

Authors:  Rhea J Longley; Karolis Bauza; Katie J Ewer; Adrian V S Hill; Alexandra J Spencer
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

9.  Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Authors:  Alicja M Chmielewska; Mariarosaria Naddeo; Stefania Capone; Virginia Ammendola; Ke Hu; Luke Meredith; Lieven Verhoye; Malgorzata Rychlowska; Rino Rappuoli; Jeffrey B Ulmer; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Geert Leroux-Roels; Peter Balfe; Krystyna Bienkowska-Szewczyk; Philip Meuleman; Jane A McKeating; Antonella Folgori
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

10.  The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment.

Authors:  Anna L Goodman; Emily K Forbes; Andrew R Williams; Alexander D Douglas; Simone C de Cassan; Karolis Bauza; Sumi Biswas; Matthew D J Dicks; David Llewellyn; Anne C Moore; Chris J Janse; Blandine M Franke-Fayard; Sarah C Gilbert; Adrian V S Hill; Richard J Pleass; Simon J Draper
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.